STOCK TITAN

InfuSystem (INFU) director awarded 24,890 stock options at $8.37 exercise price

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

InfuSystem Holdings director Ronald T. Hundzinski received a stock option grant covering 24,890 shares of common stock. The option has an exercise price of $8.37 per share, vests on May 12, 2027, and expires on May 12, 2036. It represents a compensation-related award rather than an open-market purchase or sale. Following the reported transactions, Hundzinski holds 5,000 shares of InfuSystem common stock directly.

Positive

  • None.

Negative

  • None.
Insider Hundzinski Ronald T
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 24,890 $0.00 --
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (right to buy) — 24,890 shares (Direct, null); Common Stock — 5,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 24,890 shares Stock Option (right to buy) granted to director
Exercise price $8.37 per share Conversion or exercise price of stock option
Underlying shares 24,890 shares Underlying InfuSystem common stock for the option
Common shares held 5,000 shares Total InfuSystem common stock held directly after transactions
Vesting date May 12, 2027 Option vests on this date per footnote
Expiration date May 12, 2036 Option expires on this date
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
Common Stock financial
"security_title: "Common Stock" and underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
vests financial
"The option ... vests on May 12, 2027."
exercise price financial
"conversion_or_exercise_price: "8.3700""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hundzinski Ronald T

(Last)(First)(Middle)
C/O INFUSYSTEM HOLDINGS, INC.
3851 WEST HAMLIN ROAD

(Street)
ROCHESTER HILLS MICHIGAN 48309

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
InfuSystem Holdings, Inc [ INFU ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock5,000D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$8.3705/12/2026A24,89005/12/2027(1)05/12/2036Common Stock24,890$024,890D
Explanation of Responses:
1. The option, representing the right to purchase 24,890 shares of InfuSystem Holdings, Inc. common stock, vests on May 12, 2027.
Remarks:
/s/ Kevin Whitman, Attorney-in-Fact for Ronald T. Hundzinski05/14/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did InfuSystem (INFU) director Ronald T. Hundzinski report on this Form 4?

Ronald T. Hundzinski reported receiving a new stock option grant. The award covers 24,890 shares of InfuSystem common stock as options, reflecting equity-based compensation rather than an open-market share purchase or sale, and is recorded as a direct holding.

How many InfuSystem (INFU) stock options were granted to Ronald T. Hundzinski?

He was granted options on 24,890 shares of common stock. These options give him the right to buy InfuSystem shares in the future at a fixed exercise price, subject to the vesting schedule and expiration date disclosed in the filing.

What is the exercise price of Ronald T. Hundzinski’s InfuSystem (INFU) stock options?

The options have an exercise price of $8.37 per share. This means he can buy InfuSystem common stock at $8.37 once the options vest, regardless of the market price at that time, until the options expire.

When do Ronald T. Hundzinski’s InfuSystem (INFU) stock options vest and expire?

The option vests on May 12, 2027 and expires on May 12, 2036. Vesting on that date makes the options exercisable, while the expiration date is the last day he can use them to purchase common shares.

How many InfuSystem (INFU) common shares does Ronald T. Hundzinski hold after this filing?

He holds 5,000 shares of InfuSystem common stock directly after the reported transactions. This figure reflects his direct ownership position in the company’s common shares as reported in the Form 4 data.

Is Ronald T. Hundzinski’s InfuSystem (INFU) Form 4 transaction an open-market trade?

No, the key transaction is a grant of stock options as compensation. The filing shows a derivative transaction coded as a grant or award, not a purchase or sale of shares on the open market, and includes a separate holding entry.